Journal article
A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events.
Abstract
BACKGROUND: Recommendations are broadening for the prophylaxis of atherosclerotic disorders, but aspirin is the only widely used agent. Ticlopidine hydrochloride, a new antiplatelet medication, has recently been approved for prescription in North America. We reviewed the major clinical trials of ticlopidine and derived guidelines for its use.
METHODS: Studies of ticlopidine were sought through MEDLINE for 1980 to 1990 and through bibliographies …
Authors
Haynes RB; Sandler RS; Larson EB; Pater JL; Yatsu FM
Journal
JAMA Internal Medicine, Vol. 152, No. 7, pp. 1376–1380
Publisher
American Medical Association (AMA)
Publication Date
July 1, 1992
DOI
10.1001/archinte.152.7.1376
ISSN
2168-6106